Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Recruiting · NCT06536400 · Registry updated 2024-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation | Solid Tumors | Recruiting | Phase 1 | 2024-08-05 | NCT06536400 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Haisco Pharmaceutical Group Co., Ltd. | 50 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University | Hangzhou | China | 5 |
| Beijing Cancer Hospital | Beijing | China | 208 |
| Beijing Tiantan Hospital,Capital Medical University | Beijing | China | 6 |
| Fudan University Shanghai Cancer Center | Shanghai | China | 19 |
| Guangxi Medical University Cancer Hospital | Nanning | China | 4 |
| Hunan Cancer Hospital | Changsha | China | 41 |
| Nanjing Drum Tower Hospital | Nanjing | China | 22 |
| Peking University First Hospital | Beijing | China | 163 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 1 |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou | China | 53 |
| The Third People's Hospital of Zhengzhou | Zhengzhou | China | 2 |